Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418Alfonso Cabello, Ignacio Valero, Guillermo Cuevas et al.|Open Forum Infectious Diseases|2022Cited by 12
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter CohortJorge Calderón‐Parra, Elena Múñez, Pablo Guisado‐Vasco et al.|Journal of Clinical Medicine|2023Cited by 11
Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016Ignacio Valero, Juan González‐García, Alfonso Cabello et al.|Open Forum Infectious Diseases|2020Cited by 8
Health care issues affecting transgender people living with HIV: an opportunity for improvementJesús Troya, Mar Vera, Guillermo Cuevas et al.|International Journal of STD & AIDS|2020Cited by 3